US Stock MarketDetailed Quotes
SEER Seer Inc
- 2.500
- +0.020+0.81%
Close Nov 27 16:00 ET
- 2.560
- +0.060+2.40%
Post 19:56 ET
147.42MMarket Cap-1923P/E (TTM)
2.625High2.460Low291.59KVolume2.480Open2.480Pre Close732.91KTurnover0.68%Turnover RatioLossP/E (Static)58.97MShares2.62552wk High0.43P/B107.37MFloat Cap1.51052wk Low--Dividend TTM42.95MShs Float86.550Historical High--Div YieldTTM6.65%Amplitude1.455Historical Low2.513Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Seer Inc Stock Forum
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights incl...
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s tech...
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample...
In reaction to earnings/guidance:
• $The Trade Desk (TTD.US)$+17%, $Workiva (WK.US)$ +15.3%, $Arlo Technologies (ARLO.US)$ +12%, $Array Technologies (ARRY.US)$ +10.3%, $Everbridge (EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals (CPRX.US)$ +9.4%, $Halozyme Therapeutics (HALO.US)$ +8.7%, $Velo3D (VLD.US)$ +7.6%, $CyberArk (CYBR.US)$ + 6.2%, $Haemonetics (HAE.US)$ +5.8%, $Jackson Financial (JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise (AXON.US)$ +4.8%, ...
Funds also bought about 1.07 million DraftKings shares, 949,290 JD Logistics Hong Kong-listed shares, 258,390 Pfizer shares.
Funds sold 150,115 Square shares, 84,151 Nintendo ADRs, 194,194 LendingClub shares, 82,789 Seer shares.
They also sold 226,200 Roche ADRs, 250,021 Bristol-Myers Squibb shares.
They also sold 899,10...
Funds also bought 263,485 Palantir Shares, 164,889 JD.com ADRs, 165,982 Pfizer shares and 114,476 Sema4 Holdings shares.
They sold 255,342 Roche ADRs, 184,949 Seres Therapeutics shares, 91,000 Nintendo ADRs, 104,600 Exone shares and 117,358 Seer shares.
$SOARING EAGLE ACQUISITION CORP (SRNG.US)$
$Palantir (PLTR.US)$
The funds also bought 232,610 Adaptive Biotechnologies shares, 126,744 Zillow Group shares and 316,814 TuSimple Holdings shares.
They sold 876,040 Pure Storage shares, 306,616 Seer shares, 154,558 Roche Holding ADRs, 100,687 Novartis ADRs, 60,500 Nintendo ADRs.
$SOARING EAGLE ACQUISITION CORP (SRNG.US)$
$Zillow-C (Z.US)$
No comment yet